The plant cannabinoid THCV (tetrahydrocannabivarin) decreases glucose levels and may have further beneficial effects in patients with type 2 diabetes. This is the result of research by scientists from Nottingham, London and Oxford in the UK, published in Diabetes Care. They included 62 patients with noninsulin-treated type 2 diabetes in a placebo-controlled study with CBD (100 mg twice daily), THCV (5 mg twice daily), a combination of CBD and THCV (5 mg of both cannabinoids twice daily), and a 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily).
Compared with placebo, THCV significantly decreased fasting plasma glucose and improved the function of cells in the pancreas, which are responsible for insulin production (HOMA2 beta-cell function). It also improved the values for adiponectin and apolipoprotein A. There was no difference between CBD and placebo. None of the combination treatments had a significant impact on end points. CBD and THCV were well tolerated. Authors concluded that “THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes.”
Check the study here.